Analysis of the risk associated with obstructive sleep apnea and hyperuric acid associated with end-point events in chronic kidney disease

Status

Recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2100042436

Enrollment

Unknown

Registered

2021-01-21

Start date

2021-03-01

Completion date

Unknown

Last updated

2021-04-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

bstructive sleep apnea and hyperuric acid

Interventions

OSA group vs non OSA group:Nil

Eligibility

Sex/Gender

Male

Age

18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1) a history of hyperuricemia (serum uric acid level > 420umol/L in men and postmenopausal women, and > 360umol/L in premenopausal women) for at least 5 years;With or without gout attacks; 2) Renal biopsy pathology with or without renal puncture indicated renal tubular interstitial injury; 3) Aged between 18 and 75; 4) 15 ml/min / 1.73 m2 < eGFR < 90 ml/min / 1.73 m2.

Exclusion criteria

Exclusion criteria: 1) Complications: systemic lupus erythematosus, rheumatoid arthritis and other immune diseases; Severe infection; Malignant tumor; Active hepatitis B; Tuberculosis (TB).Kidney stones or hydronephrosis; Isolated kidney; Bleeding tendency and systemic failure; 2) Patients after kidney transplantation or dialysis; 3) Patients with diabetes mellitus.

Design outcomes

Primary

Measure	Time frame
AHI;	—

Countries

China

Contacts

Public ContactHe LI

600 Yishan Road, Xuhui District, Shanghai, China

892314965@qq.com+86 18818209863

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026